Alfavision Overseas (India) Limited (ALFAVIO.BO)
INR 12.69
(1.44%)
INR 12.69
(1.44%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 10.46 Million INR | -66.79% |
| 2022 | 31.5 Million INR | -46.16% |
| 2021 | 58.51 Million INR | 1.86% |
| 2020 | 57.44 Million INR | 37.83% |
| 2019 | 41.67 Million INR | 30.69% |
| 2018 | 31.88 Million INR | 28.67% |
| 2017 | 24.78 Million INR | 177.22% |
| 2016 | 8.94 Million INR | 48.44% |
| 2015 | 6.02 Million INR | -16.64% |
| 2014 | 7.22 Million INR | 71.86% |
| 2013 | 4.2 Million INR | 17.48% |
| 2012 | 3.57 Million INR | 207.48% |
| 2011 | 1.16 Million INR | -25.02% |
| 2010 | 1.55 Million INR | 81.31% |
| 2009 | 856 Thousand INR | -77.63% |
| 2008 | 3.82 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.37 Million INR | 117.43% |
| 2023 Q4 | -7.89 Million INR | -207.26% |
| 2023 Q3 | 7.35 Million INR | 29.28% |
| 2023 Q2 | 5.69 Million INR | 16.98% |
| 2023 Q1 | 4.86 Million INR | 125.55% |
| 2023 FY | 10.46 Million INR | -66.79% |
| 2022 Q2 | 13.64 Million INR | 63.85% |
| 2022 Q3 | 7.38 Million INR | -45.88% |
| 2022 Q4 | -19.03 Million INR | -357.74% |
| 2022 Q1 | 8.33 Million INR | -71.11% |
| 2022 FY | 31.5 Million INR | -46.16% |
| 2021 Q4 | 28.83 Million INR | 284.35% |
| 2021 Q1 | 6.88 Million INR | -69.75% |
| 2021 Q3 | 7.5 Million INR | -42.45% |
| 2021 Q2 | 13.03 Million INR | 89.33% |
| 2021 FY | 58.51 Million INR | 1.86% |
| 2020 Q2 | 5.77 Million INR | 74.71% |
| 2020 FY | 57.44 Million INR | 37.83% |
| 2020 Q1 | 3.3 Million INR | -69.76% |
| 2020 Q3 | 18.92 Million INR | 227.6% |
| 2020 Q4 | 22.76 Million INR | 20.31% |
| 2019 FY | 41.67 Million INR | 30.69% |
| 2019 Q1 | 814 Thousand INR | -96.11% |
| 2019 Q2 | 10.11 Million INR | 1142.01% |
| 2019 Q3 | 13.33 Million INR | 31.88% |
| 2019 Q4 | 10.93 Million INR | -18.0% |
| 2018 Q1 | 3.87 Million INR | 80.2% |
| 2018 FY | 31.88 Million INR | 28.67% |
| 2018 Q4 | 20.9 Million INR | 2481.11% |
| 2018 Q3 | 810 Thousand INR | -72.62% |
| 2018 Q2 | 2.95 Million INR | -23.68% |
| 2017 Q2 | 2.78 Million INR | 105.16% |
| 2017 FY | 24.78 Million INR | 177.22% |
| 2017 Q1 | 1.35 Million INR | -80.71% |
| 2017 Q3 | 4.07 Million INR | 46.44% |
| 2017 Q4 | 2.15 Million INR | -47.2% |
| 2016 Q4 | 7.03 Million INR | 1166.85% |
| 2016 Q3 | 555 Thousand INR | -3.48% |
| 2016 FY | 8.94 Million INR | 48.44% |
| 2016 Q1 | 1.57 Million INR | 96.25% |
| 2016 Q2 | 575 Thousand INR | -63.38% |
| 2015 Q4 | 800 Thousand INR | -25.93% |
| 2015 FY | 6.02 Million INR | -16.64% |
| 2015 Q3 | 1.08 Million INR | -7.3% |
| 2015 Q2 | 1.16 Million INR | -51.86% |
| 2015 Q1 | 2.42 Million INR | -34.39% |
| 2014 Q3 | 508 Thousand INR | 190.29% |
| 2014 FY | 7.22 Million INR | 71.86% |
| 2014 Q1 | 2.9 Million INR | 315.76% |
| 2014 Q2 | 175 Thousand INR | -93.97% |
| 2014 Q4 | 3.68 Million INR | 626.08% |
| 2013 Q4 | 697.76 Thousand INR | 1416.53% |
| 2013 FY | 4.2 Million INR | 17.48% |
| 2013 Q1 | 1 Million INR | -42.21% |
| 2013 Q2 | 2.52 Million INR | 152.35% |
| 2013 Q3 | -53 Thousand INR | -102.1% |
| 2012 Q1 | 303 Thousand INR | 23.67% |
| 2012 Q2 | 166 Thousand INR | -45.21% |
| 2012 FY | 3.57 Million INR | 207.48% |
| 2012 Q3 | 381 Thousand INR | 129.52% |
| 2012 Q4 | 1.73 Million INR | 354.61% |
| 2011 FY | 1.16 Million INR | -25.02% |
| 2011 Q3 | - INR | 0.0% |
| 2011 Q4 | 245 Thousand INR | 0.0% |
| 2010 FY | 1.55 Million INR | 81.31% |
| 2010 Q4 | 827 Thousand INR | 0.0% |
| 2009 Q4 | 149 Thousand INR | 0.0% |
| 2009 FY | 856 Thousand INR | -77.63% |
| 2008 FY | 3.82 Million INR | 0.0% |
| 2008 Q4 | 334 Thousand INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Biocon Limited | 91.73 Billion INR | 99.989% |
| Blue Jet Healthcare Limited | 3.15 Billion INR | 99.669% |
| Concord Biotech Limited | 6.11 Billion INR | 99.829% |
| Dishman Carbogen Amcis Limited | 4.9 Billion INR | 99.787% |
| FERMENTA BIOTECH LIMITED | 1.82 Billion INR | 99.426% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.65 Million INR | -533.712% |
| Lyka Labs Limited | 145.95 Million INR | 92.833% |
| Panacea Biotec Limited | 1.35 Billion INR | 99.228% |
| SAMSRITA LABS LIMITED | -1.28 Million INR | 915.31% |
| Servoteach Industries Limited | - INR | -Infinity% |
| SMS Lifesciences India Limited | 329.57 Million INR | 96.826% |
| Supriya Lifescience Limited | 2.65 Billion INR | 99.606% |
| Syngene International Limited | 12.43 Billion INR | 99.916% |
| TAKE Solutions Limited | 183.42 Million INR | 94.297% |
| Titan Biotech Limited | 884.66 Million INR | 98.818% |
| Transgene Biotek Limited | -1.69 Million INR | 718.262% |
| Vanta Bioscience Limited | 7.12 Million INR | -46.924% |